Search results
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF...
WKRN Nashville· 4 days agoFood and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic ...
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
WTNH-TV New Haven· 5 days agoThe primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was ...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
FOX21 Colorado Springs· 14 hours agoPhase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 23, 2024 ...
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...
Digital Journal· 2 days agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it ...
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and...
Morningstar· 6 days agoInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis - 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Zacks via Yahoo Finance· 4 days agoGilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 3 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 2 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From...
WPRI Providence· 4 days agoBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients ...